These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 1813974

  • 1. [Diurnal worsening in Parkinson patients treated with levodopa].
    Piccini P, Del Dotto P, Pardini C, D'Antonio P, Rossi G, Bonuccelli U.
    Riv Neurol; 1991; 61(6):219-24. PubMed ID: 1813974
    [Abstract] [Full Text] [Related]

  • 2. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS, Kirby L, Kumar D, Cullen EI, Pratt RD, Hahne WA.
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [Abstract] [Full Text] [Related]

  • 3. Diurnal motor variations to repeated doses of levodopa in Parkinson's disease.
    Bonuccelli U, Del Dotto P, Lucetti C, Petrozzi L, Bernardini S, Gambaccini G, Rossi G, Piccini P.
    Clin Neuropharmacol; 2000 Nov; 23(1):28-33. PubMed ID: 10682228
    [Abstract] [Full Text] [Related]

  • 4. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [Abstract] [Full Text] [Related]

  • 5. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
    Nutt JG, Carter JH, Lea ES, Woodward WR.
    Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720
    [Abstract] [Full Text] [Related]

  • 6. The Sydney multicentre study of Parkinson's disease. The first 18 months.
    Hely MA, Morris JG, Rail D, O'Sullivan DJ, Williamson PM, Genge S, Reid WG, Broe GA.
    Med J Aust; 1987 Feb 16; 146(4):195-8. PubMed ID: 3553878
    [Abstract] [Full Text] [Related]

  • 7. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
    Grimes JD, Delgado MR.
    Clin Neuropharmacol; 1985 Feb 16; 8(1):73-7. PubMed ID: 3978651
    [Abstract] [Full Text] [Related]

  • 8. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
    Hauser RA, Holford NH.
    Mov Disord; 2002 Sep 16; 17(5):961-8. PubMed ID: 12360545
    [Abstract] [Full Text] [Related]

  • 9. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
    Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D, Esterlitz J.
    Ann Neurol; 1995 Nov 16; 38(5):771-7. PubMed ID: 7486869
    [Abstract] [Full Text] [Related]

  • 10. [Comparison of administration of low doses of bromocriptine and levodopa in the early treatment of Parkinson disease].
    Sternić N, Kostić V.
    Srp Arh Celok Lek; 1992 Nov 16; 120(1-2):1-5. PubMed ID: 1641693
    [Abstract] [Full Text] [Related]

  • 11. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
    Pahwa R, Lyons K, McGuire D, Silverstein P, Zwiebel F, Robischon M, Koller WC.
    Mov Disord; 1997 Sep 16; 12(5):677-81. PubMed ID: 9380047
    [Abstract] [Full Text] [Related]

  • 12. Bromocriptine: long-term low-dose therapy in Parkinson's disease.
    Teychenne PF, Bergsrud D, Elton RL, Racy A.
    Clin Neuropharmacol; 1986 Sep 16; 9(2):138-45. PubMed ID: 3708599
    [Abstract] [Full Text] [Related]

  • 13. Low-dosage treatment in de novo patients with Parkinson's disease: a prospective study.
    van der Drift JH.
    Adv Neurol; 1987 Sep 16; 45():529-34. PubMed ID: 3825731
    [Abstract] [Full Text] [Related]

  • 14. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I, Gawel MJ, Riopelle RJ, Bouchard S.
    Can J Neurol Sci; 1987 Nov 16; 14(4):576-80. PubMed ID: 3319120
    [Abstract] [Full Text] [Related]

  • 15. Low-dose, slow-increase bromocriptine in patients with progressive Parkinson's disease and complications of levodopa therapy.
    Stern MB, Vernon GM, Gollomp SM, Hurtig HI.
    Bull Clin Neurosci; 1986 Nov 16; 51():52-6. PubMed ID: 3455244
    [Abstract] [Full Text] [Related]

  • 16. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, Aquilonius SM, Askmark H.
    Neurology; 2005 Jan 25; 64(2):216-23. PubMed ID: 15668416
    [Abstract] [Full Text] [Related]

  • 17. Treatment of parkinson's disease with bromocriptine.
    Lieberman A, Kupersmith M, Estey E, Goldstein M.
    N Engl J Med; 1976 Dec 16; 295(25):1400-4. PubMed ID: 989885
    [Abstract] [Full Text] [Related]

  • 18. Long-term efficacy of controlled-release carbidopa/levodopa in patients with advanced Parkinson's disease.
    Mark MH, Sage JI.
    Ann Clin Lab Sci; 1989 Dec 16; 19(6):415-21. PubMed ID: 2690730
    [Abstract] [Full Text] [Related]

  • 19. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
    Giménez-Roldán S, Tolosa E, Burguera JA, Chacón J, Liaño H, Forcadell F.
    Clin Neuropharmacol; 1997 Feb 16; 20(1):67-76. PubMed ID: 9037575
    [Abstract] [Full Text] [Related]

  • 20. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH, Ha JH, Cho IS, Lee MC.
    J Neurol; 2003 Jan 16; 250(1):90-6. PubMed ID: 12527999
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.